The elimination of Hepatitis C as a global public health threat

在澳大利亚，超过23万人患有慢性丙型肝炎病毒感染，如果不及时治疗，估计每年的医疗费用超过65亿美元。新型高效HCV药物——直接作用抗病毒药物（DAAs）治愈率达90%。DAAs将彻底改变丙型肝炎病毒的护理——我们现在可以阻止丙型肝炎病毒相关的死亡和传播，使消除丙型肝炎病毒成为可能。该项目赠款将直接为全球消除丙型肝炎病毒和澳大利亚实现到2030年消除丙型肝炎做出贡献。

In Australia over 230,000 people live with chronic HCV infection, with an estimated annual health care cost of over > $6.5 billion if left untreated. New highly effective HCV medications - direct acting antivirals (DAAs) have a cure rate of > 90%. DAAs will revolutionise HCV care - we can now stop HCV related deaths and transmission making HCV elimination possible. This Program Grant will directly contribute to the global response to HCV elimination and Australia achieving elimination by 2030.